New worldwide seasonal flu immunization strategies with expanded target populations, plus the ever-increasing threat of a worldwide outbreak of a highly infectious and deadly influenza virus variant are driving the demand for preventative vaccines.

The major defense against influenza is vaccination; however, global production capacity is insufficient to supply growing demand for both pandemic and seasonal vaccines.

Our iBioLaunch™ platform, with its rapid, unparalleled scale-up capacity and cost efficiency, was developed in response to the pressing need for alternative approaches to the limitations of current vaccine production technologies, particularly where large scale or rapid inoculation is needed.

We are developing proprietary vaccines composed of viral surface antigens directed against both human seasonal and avian influenza strains. Preclinical studies of immunogenicity and protective efficacy of these novel sub-unit vaccine candidates are showing significant promise.